WASHINGTON, Jan 17 (Reuters) - Valera Pharmaceuticals Inc., a developer of treatments for urological and endocrine conditions, on Tuesday set its planned initial public offering at 3.75 million shares for between $10 and $12 per share. UBS Investment Bank and Banc of America Securities LLC will a group of underwriters who will have the option to by another 562,500 shares in the event of heavy demand.
